Discover more projects across a range of sectors and discipline — from AI to cleantech to social innovation.
Prostate cancer is the most common malignancy in men and a major cause of cancer deaths. Androgen deprivation therapy (ADT) is the first-line therapy for metastatic prostate cancer but invariable the cancer regrows despite the androgen deprivation – this regrowth is termed castrate resistant prostate cancer. We have discovered that expression of a specific gene (Semaphorin 3C) is associated with the emergence of castrate resistant prostate cancer. The Ong laboratory has developed an inhibitor to the Semaphorin 3C pathway, and the purpose of the current study is to determine what genetic alterations in the tumour cells can result in the emergence of resistance to inhibition of Semophorin 3C signaling.
Christopher J Ong
STEMCELL Technologies Canada Inc
University of British Columbia
Find the perfect opportunity to put your academic skills and knowledge into practice!Find Projects
The strong support from governments across Canada, international partners, universities, colleges, companies, and community organizations has enabled Mitacs to focus on the core idea that talent and partnerships power innovation — and innovation creates a better future.